Article Versions Notes

Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M, Nagumo Y, Fujimoto A, Arai T, Sato H, et al. TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab. International Journal of Molecular Sciences. 2024; 25(13):7444. https://doi.org/10.3390/ijms25137444

Isoda, Bunpei, Shuya Kandori, Tomokazu Sazuka, Takahiro Kojima, Satoshi Nitta, Masanobu Shiga, Yoshiyuki Nagumo, Ayumi Fujimoto, Takayuki Arai, Hiroaki Sato, and et al. 2024. "TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab" International Journal of Molecular Sciences 25, no. 13: 7444. https://doi.org/10.3390/ijms25137444

Isoda, B., Kandori, S., Sazuka, T., Kojima, T., Nitta, S., Shiga, M., Nagumo, Y., Fujimoto, A., Arai, T., Sato, H., Mathis, B. J., Wu, C. -L., Jan, Y. -H., Ichikawa, T., & Nishiyama, H. (2024). TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab. International Journal of Molecular Sciences, 25(13), 7444. https://doi.org/10.3390/ijms25137444